Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

AMLM26 INTERCEPT : AMLM26- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial - The Master Protocol

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Treatment<br/>TrialTypeTreatment
Trial

UnknownPhase Unknown

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Early Detection, Diagnosis, and Prognosis,Treatment | Blood / Myeloma / LymphomaAcute Myeloid Leukaemia

Trial Overview Read MoreRead more

This is the master protocol for the INTERCEPT study, which is a multi-arm treatment trial for people with acute myeloid leukaemia.
 

This trial is treating patients with acute myeloid leukaemia.

This is a treatment trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

AMLM26- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial - The Master Protocol

Cooperative Group

Australasian Leukaemia and Lymphoma Group (ALLG)

Summary

Participants enter the study in first or second morphologic remission (CR or CRi) with known and trackable MRD marker(s). The relevant MRD marker(s) will be monitored as per standard practice until evidence of MRD failure and/or morphological relapse. Participants will then be allocated to the best available treatment option at the time. If there is more than one treatment option of equal value for the participant, they will be randomised to one option. As this is a platform trial, new treatment arms may be added and others may be removed if ineffective. New targeted treatment domains may be created when there is sufficient evidence available to enable biomarker-driven enrichment cohorts to be accrued to more rapidly. In domains with a single treatment arm, proof of concept analyses of the primary efficacy endpoint will commence after the first 10 patients have had the required assessments or withdrawn earlier. In domains with more than one treatment arm and with a pre-planned comparison of the arms, the timing of the first analysis will be determined when these arms are added to the trial and information included in the specific treatment arm's linked ANZCTR entry.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Jessica Ahern
PCCTU.HaemA@petermac.org

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next